[Cardioxane in pediatric oncohematology].
The tolerance of cardioxan (JCRF-187, dexrazoxan), an ethylenediamine tetra-acetic acid analog and a Chiron Company product, administered to pediatric oncohematological patients, is discussed. The drug was used in 37 cases of acute lymphoblastic and non-lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's disease treated by polychemotherapy including anthracycline antibiotics administration. No untoward side-effects or inhibition of the therapeutic effect were observed.
Kurmashov
V I
VI
Gavrilova
I E
IE
Maiakova
S A
SA
Popa
A V
AV
Morozova
O V
OV
Ivanova
L F
LF
Kurdiukov
B V
BV
Gavrikova
N V
NV
Il'iashenko
V V
VV
Terzich
M
M
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D006321:Heart / Q000187:drug effects*; D006801:Humans; D011929:Razoxane / Q000494:pharmacology*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D011929:Razoxane